Jonas Schiffmann1, Pierre I Karakiewicz2,3, Michael Rink4, L Manka5, Georg Salomon6, Derya Tilki4,6, Lars Budäus6, Raisa Pompe2,6, Sami-Ramzi Leyh-Bannurah4, Alexander Haese6, P Hammerer5, Hartwig Huland6, Markus Graefen6, Pierre Tennstedt6. 1. Department of Urology, Academic Hospital Braunschweig, Salzdahlumerstrasse 90, 38126, Brunswick, Germany. schiffmann.jonas@gmx.de. 2. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. 3. Department of Urology, University of Montreal Health Center, Montreal, Canada. 4. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Urology, Academic Hospital Braunschweig, Salzdahlumerstrasse 90, 38126, Brunswick, Germany. 6. Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
INTRODUCTION: Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free survival after radical prostatectomy (RP) is still inconsistent. METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox regression analyses examined the impact of obesity on metastases after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free survival according to body mass index (kg/m2) (BMI) strata (≥ 30 vs. < 25). RESULTS: Of 13,667 individuals, 1990 (14.6%) men were obese (BMI ≥ 30). Median follow-up was 36.4 month (IQR 13.3-60.8). Obese patients were less likely to exhibit metastases after RP (HR 0.7, 95% CI 0.5-0.97, p = 0.03). Similarly, after propensity score adjustment, obesity was associated with increased metastases-free survival (log rank p = 0.001). CONCLUSION: We recorded the obesity paradox phenomenon in PCa patients. In particular, high BMI (≥ 30) was associated with decreased risk of metastases after RP, despite an increased risk being anticipated. Whether statin use might have affected the results was not assessed. Further research is needed to unravel the controversially debated association between obesity and PCa.
INTRODUCTION:Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free survival after radical prostatectomy (RP) is still inconsistent. METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox regression analyses examined the impact of obesity on metastases after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free survival according to body mass index (kg/m2) (BMI) strata (≥ 30 vs. < 25). RESULTS: Of 13,667 individuals, 1990 (14.6%) men were obese (BMI ≥ 30). Median follow-up was 36.4 month (IQR 13.3-60.8). Obesepatients were less likely to exhibit metastases after RP (HR 0.7, 95% CI 0.5-0.97, p = 0.03). Similarly, after propensity score adjustment, obesity was associated with increased metastases-free survival (log rank p = 0.001). CONCLUSION: We recorded the obesity paradox phenomenon in PCa patients. In particular, high BMI (≥ 30) was associated with decreased risk of metastases after RP, despite an increased risk being anticipated. Whether statin use might have affected the results was not assessed. Further research is needed to unravel the controversially debated association between obesity and PCa.
Entities:
Keywords:
BMI; Body mass index; Metastases; Obesity; Obesity paradox; Outcomes; Prostate cancer; Radical prostatectomy; Survival
Authors: Felix K H Chun; Alberto Briganti; Markus Graefen; Andreas Erbersdobler; Jochen Walz; Thorsten Schlomm; Mirja Meschke; Alexander Haese; Luc Valiquette; Hartwig Huland; Pierre I Karakiewicz Journal: Eur J Cancer Date: 2006-12-01 Impact factor: 9.162
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Int J Cancer Date: 2017-11-16 Impact factor: 7.396
Authors: Joanna Budna-Tukan; Monika Świerczewska; Martine Mazel; Wojciech A Cieślikowski; Agnieszka Ida; Agnieszka Jankowiak; Andrzej Antczak; Michał Nowicki; Klaus Pantel; David Azria; Maciej Zabel; Catherine Alix-Panabières Journal: Cancers (Basel) Date: 2019-06-10 Impact factor: 6.639